Device Trial Radar · NCT05383651
Post Market, Prospective Multicenter Observational Study of the Safety and Performance of Bellavista Ventilator
Last checked: Nov 20, 2026Latest source record: Sep 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Feb 1, 2023
Primary completion
May 31, 2024
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- Vyaire MedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 20, 2022
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective post market clinical follow up (PMCF) study will evaluate the safety and performance of bellavista ventilator and the iFlow sensors in daily clinical routine.
Conditions
- Ventilation Therapy; Complications
Interventions
bellavista 1000Device
observational use of Bellavista 1000 ventilator in adult ventilated patients
bellavista 1000 neoDevice
observational use of Bellavista 1000 ventilator in neonatal ventilated patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ventilator Performance - Relationship between the set and observed Positive End-Expiratory Pressure (PEEP)Time frame: through study completion, an average of 12 hours- 24 days
4 more outcomes with a free account
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
University Health Network
Toronto, Ontario, Canada
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.